Literature DB >> 12690299

Expression of the c-kit receptor in choroidal melanomas.

Frédéric Mouriaux1, Zoulika Kherrouche, Claude-Alain Maurage, François-Xavier Demailly, Pierre Labalette, Simon Saule.   

Abstract

The KIT gene encodes c-kit, a transmembrane receptor that has tyrosine kinase activity and plays a role in haematopoiesis, gametogenesis and melanogenesis. The c-kit protein is found in normal cutaneous and choroidal melanocytes, and there is evidence that expression is lost in melanoma. Expression of c-kit was analysed in 57 paraffin-embedded sections of choroidal melanoma specimens and three choroidal melanoma cell lines using immunochemistry and Western blotting. Of the tumour specimens, 75% stained positively for c-kit with a membrane pattern of reactivity. Of the six patients who underwent proton beam therapy before enucleation, five tumours exhibited no c-kit immunoreactivity and the other tumour demonstrated weak staining. Of the three melanoma cell lines used, c-kit expression was observed in only one. No correlations between c-kit positivity and parameters such as cell type, largest macroscopic tumour dimension, scleral invasion or pigmentation were observed. In contrast, a significant positive association was found between c-kit staining and mitotic activity (P = 0.02). However, c-kit expression did not significantly influence survival when evaluated by univariate analysis. In conclusion, c-kit is expressed in most choroidal melanoma tumours. Further analysis should provide new insights into the mechanisms underlying the molecular and cellular changes in choroidal melanomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12690299     DOI: 10.1097/00008390-200304000-00008

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  8 in total

Review 1.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma.

Authors:  Nicolas Penel; Corinne Delcambre; Xavier Durando; Stéphanie Clisant; Mohamed Hebbar; Sylvie Negrier; Charles Fournier; Nicolas Isambert; Frédéric Mascarelli; Frédéric Mouriaux
Journal:  Invest New Drugs       Date:  2008-06-13       Impact factor: 3.850

3.  Therapeutic opportunities in noncutaneous melanoma.

Authors:  D K Wilkins; P D Nathan
Journal:  Ther Adv Med Oncol       Date:  2009-07       Impact factor: 8.168

4.  Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.

Authors:  Armelle Calipel; Solange Landreville; Arnaud De La Fouchardière; Frédéric Mascarelli; Michel Rivoire; Nicolas Penel; Frédéric Mouriaux
Journal:  Clin Exp Metastasis       Date:  2014-03-21       Impact factor: 5.150

Review 5.  The biology and management of uveal melanoma.

Authors:  Takami Sato; Fei Han; Akira Yamamoto
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

6.  Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.

Authors:  Rosaria Gangemi; Valentina Mirisola; Gaia Barisione; Marina Fabbi; Antonella Brizzolara; Francesco Lanza; Carlo Mosci; Sandra Salvi; Marina Gualco; Mauro Truini; Giovanna Angelini; Simona Boccardo; Michele Cilli; Irma Airoldi; Paola Queirolo; Martine J Jager; Antonio Daga; Ulrich Pfeffer; Silvano Ferrini
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

7.  The role of c-kit and imatinib mesylate in uveal melanoma.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Jean Claude Marshall; Zelia Maria Correa; Rubens Belfort; Miguel N Burnier
Journal:  J Carcinog       Date:  2005-10-19

8.  Expression analysis of genes and pathways associated with liver metastases of the uveal melanoma.

Authors:  Yuanyuan Zhang; Yong Yang; Lei Chen; Jianhong Zhang
Journal:  BMC Med Genet       Date:  2014-03-05       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.